Vol 28, No 5 (2021)
Letter to the Editor
Published online: 2021-07-07
Mortality reduction with levosimendan in patients with heart failure: Current evidence is underpowered
Abstract
Not available
References
- Jaguszewski MJ, Gasecka A, Targonski R, et al. Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis. Cardiol J. 2021; 28(3): 492–493.
- Sanfilippo F, Knight JB, Scolletta S, et al. Levosimendan for patients with severely reduced left ventricular systolic function and/or low cardiac output syndrome undergoing cardiac surgery: a systematic review and meta-analysis. Crit Care. 2017; 21(1): 252.
- Afshari A, Wetterslev J. When may systematic reviews and meta-analyses be considered reliable? Eur J Anaesthesiol. 2015; 32(2): 85–87.
- Barili F, Parolari A, Kappetein PA, et al. Statistical Primer: heterogeneity, random- or fixed-effects model analyses? Interact Cardiovasc Thorac Surg. 2018; 27(3): 317–321.
- Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007; 297(17): 1883–1891.